Pulsante® SPG Stimulation for Cluster Headache
First-of-its-kind microstimulator designed for cluster headache patients.
The Pulsante SPG Microstimulator System is designed to provide on-demand therapy to relieve the acute, debilitating pain of cluster headache. This targeted therapy offers a minimally invasive option without dose restrictions or systemic side effects.1
Pulsante therapy works by using a wireless handheld remote controller to power a microstimulator (about the size of an almond) that is inserted near the SPG nerve bundle behind the cheek. The Pulsante SPG Microstimulator directs mild electrical pulses to interfere with pain messages reaching the brain. During treatment, you are in control of the intensity of the therapy and can turn it on and off as needed.
Pulsante Therapy is a non-drug treatment option and does not preclude the future use of other therapies. You can remain on your current medications, although in a clinical study, many patients reduced the amount they took or stopped using medications altogether. Always consult your doctor before making any changes to your medical regime.
Benefits of Pulsante Therapy
People choose Pulsante Therapy over other headache treatments because it offers:
- Minimally invasive approach through a small oral incision
- No visible scars
- On-demand treatment
- Non-drug treatment
- No dose restrictions
- Proven safety and efficacy
Robust clinical studies report that patients treated with Pulsante Therapy experienced:
- 90% satisfaction2
- Rapid pain relief in 67% of attacks within 15 minutes3
- 60% reduction in acute medications3
Learn more about the clinical outcomes.
- Jürgens, et al. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia, 2016; 0:1-12.
- Assaf, et al. Technical and surgical aspects of the sphenopalatine ganglion (SPG) microstimulator insertion procedure. International Journal of Oral & Maxillofacial Surgery, 2015.
- Schoenen, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia, 2013; 33:816-30.